Metoprolol pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers for "metoprolol pharmacokinetics"
Metoprolol Pharmacokinetics: Key Determinants and Variability
CYP2D6 Genotype and Metoprolol Metabolism
Metoprolol is primarily metabolized by the enzyme CYP2D6, which shows significant genetic variability among individuals. This genetic diversity leads to marked differences in how people process metoprolol. Poor metabolizers have much higher peak plasma concentrations, area under the curve (AUC), and elimination half-life, and much lower oral clearance compared to extensive and ultrarapid metabolizers. For example, differences in these pharmacokinetic parameters can be as high as 13- to 15-fold between ultrarapid and poor metabolizers. Additionally, the metabolism of metoprolol is enantio-selective, with ultrarapid and extensive metabolizers processing the R-enantiomer about 40% more than the S-enantiomer. These findings highlight the importance of considering CYP2D6 genotype for personalized dosing of metoprolol 1479.
Route of Administration, Bioavailability, and Dose-Dependence
Metoprolol can be administered orally or intravenously, with oral bioavailability typically ranging from 40% to 50% due to first-pass metabolism. After oral administration, the plasma concentration of metoprolol increases in a dose-dependent manner, with higher doses leading to higher maximum plasma concentrations (C_max), longer time to reach C_max (T_max), and greater AUC. The elimination half-life is about three hours, and the effect on heart rate is most pronounced within the first hour after oral dosing. The ratio of equipotent oral to intravenous doses is about 2.5, reflecting the reduced bioavailability of oral metoprolol 23.
Impact of Disease States and Drug Interactions
Metoprolol pharmacokinetics can be altered in patients with hepatic or renal impairment. Hepatic cirrhosis leads to decreased clearance, while renal impairment can increase clearance after intravenous administration. In patients with acute myocardial infarction, steady-state C_max is higher compared to healthy individuals. Numerous studies have also shown that co-administration with other drugs can significantly change metoprolol’s clearance, C_max, and AUC, though food does not appear to have a significant effect on these parameters .
Age, Sex, and Pregnancy Effects
Age has a modest effect on metoprolol pharmacokinetics. Elderly individuals have similar plasma concentrations of metoprolol compared to younger adults, but higher levels of certain active metabolites and reduced urinary excretion of unchanged drug. Chronic dosing leads to higher plasma concentrations than predicted from single doses . Sex differences have also been observed, with women generally having higher C_max and AUC values than men 26.
During pregnancy, metoprolol clearance increases significantly, especially in mid and late pregnancy, likely due to physiological changes that enhance drug metabolism. This means pregnant women may require higher or more frequent dosing to achieve therapeutic effects. However, infant exposure through breast milk remains very low (<1% of the maternal dose) .
Enantiomer-Specific and Ethnic Differences
Metoprolol is administered as a racemic mixture, but the S-enantiomer often has higher C_max, T_max, and AUC than the R-enantiomer. In Chinese populations, specific CYP2D6 polymorphisms (such as CYP2D6*10A) are associated with higher plasma concentrations and lower metabolite excretion, suggesting that lower doses may be appropriate for individuals with these genotypes 29.
Animal Studies and Formulation Differences
Animal studies show that sex and species can significantly affect metoprolol pharmacokinetics, with notable differences in peak plasma levels between male and female rodents. Modified-release formulations also display different absorption kinetics in animal models, with reservoir formulations behaving similarly across species, while matrix formulations show species-specific differences 610.
Conclusion
Metoprolol pharmacokinetics are highly variable and influenced by genetic factors (especially CYP2D6 genotype), route of administration, disease states, age, sex, pregnancy, and drug interactions. Personalized dosing based on these factors can help optimize therapy and minimize adverse effects. Understanding these variables is essential for clinicians to make informed decisions about metoprolol use in diverse patient populations.
Sources and full results
Most relevant research papers on this topic